For research use only. Not for therapeutic Use.
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.
| Catalog Number | I047325 |
| Purity | ≥95% |
| Reference | [1] McGuinness JE, et al. Expert Opin Biol Ther. 2021 Jul;21(7):903-913. |
